-
Russia pummels Kyiv, killing three and denting peace hopes
-
Subdued Trump left waiting for 'big hug' from Xi
-
Slot has 'every reason to believe' he will remain as Liverpool boss
-
British PM battles to stay in power amid rebellion
-
Ex-Philippine drug war enforcer flees Senate refuge
-
U2 surprise fans in Mexico City to shoot music video
-
Asia stocks uneven as investors assess high-stakes Trump-Xi talks, AI rally
-
Burberry returns to full-year profit on turnaround plan
-
Spiky, polarising, rarely dull: ups and downs of rugby's Eddie Jones
-
Denmark, Australia in the spotlight in Eurovision second semi
-
Heavy Russian strikes on Kyiv kill one, wound 31
-
Xi warns Trump on Taiwan at Beijing summit
-
Iran war and oil dominate BRICS meet in India
-
Bone appetit: Paris pups lap up treats at dog-centric spots
-
Kohli senses end after roaring back to form with IPL century
-
India bars sugar exports until September
-
Madonna, Shakira, BTS to headline first World Cup final half-time show
-
Japan takes 'half step' toward fixing slow retrial system
-
Honda posts operating loss, first since 1957
-
Madonna, Shakira, BTS to headline World Cup final half-time show
-
A quarter of World Cup games risk searing heat: scientists
-
Six hantavirus cruise passengers head to Australia
-
Suspect detained in Philippine senate gunfire: police
-
Cavs top Pistons in overtime for 3-2 series lead
-
Canadian football ready for World Cup coming out party
-
US court suspends sanctions on UN expert on Palestinians
-
Asia markets mixed as Trump-Xi summit, AI trade dominate
-
'Promised to us': The Israelis dreaming of settling south Lebanon
-
'Rare, meaningful': North Korean football team ventures into South
-
In-form Messi hits brace as Miami win 5-3 at Cincinnati in MLS
-
Historic Swiss solar-powered plane crashes into sea
-
A woman UN leader is 'historical justice,' says Ecuadoran contender for top job
-
Indian pharma fuels Africa's 'zombie drug' and opioid crisis
-
After months of blackout, Iran gives internet to select few
-
Wood urges New Zealand to 'create some history' at World Cup
-
In Washington, the fight to preserve Black cemeteries
-
US children's book author sentenced to life after poisoning husband
-
Emotional Vin Diesel leads 'Fast and Furious' tribute in Cannes
-
NAV Fund Services (Ireland) Ltd. Expands European Fund Servicing Offering to Support UCITS Funds
-
AVI Urges the Dismissal of Two Directors at Wacom
-
PLAS-LABS Simplifies Scientific Validation With Automated Citation Tracking Powered by Bioz
-
Battery X Metals Achieves Milestone with Delivery of Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Machine Featuring Design Enhancements, Advancing Strategic Commercialization Initiatives
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - May 14
-
Akkodis Recognized in HFS Horizons 2026 Report for Enterprise Ready Agentic AI Services
-
Lexus Of Oakville Recognized for Redefining the Luxury Dealership Experience With 2026 Consumer Choice Award
-
US renews offer of $100 mn to Cuba if it cooperates
-
City still 'alive' but need Arsenal slip: Guardiola
-
Man City ease past Palace to keep pressure on Arsenal
-
Alaves end champions Barca's bid for 100-point record
-
US jury begins deliberations on 737 MAX victim suit against Boeing
US authorizes fourth Covid shot for over 50s
The United States Tuesday authorized a fourth dose of either the Pfizer-BioNTech or Moderna Covid-19 vaccines for people 50 and older, as authorities warn of a possible new wave driven by the BA.2 variant.
The Food and Drug Administration (FDA) said in a statement it had based its decision on emerging evidence that an additional booster, given four months after the last, improved protection against severe Covid and wasn't associated with new safety concerns.
Additionally, people with immune compromising conditions who have already received four shots, with their latest at least four months ago, are now eligible for a fifth dose.
That includes people living with certain organ transplants.
The Pfizer vaccine will be available to immune compromised people aged 12 and over, while the Moderna vaccine will be available to those 18 and up.
"Current evidence suggests some waning of protection over time against serious outcomes from Covid-19 in older and immunocompromised individuals," senior FDA scientist Peter Marks said, explaining the decision.
The FDA said data from Israel, which had studied the effects of a fourth dose given four months after the third on 700,000 people, found the extra shot was safe.
It also cited data from a study of 154 health workers whose antibody levels, including against the Delta and Omicron variants, were restored to high levels two weeks after their fourth doses.
A study published by Israeli researchers in the New England Journal of Medicine this month indicated that three doses of current generation mRNA vaccines have hit a ceiling in terms of the immune response generated.
In other words, while three doses brings immunity levels to new heights, the fourth dose restores antibody levels to where they previously were shortly after the third.
Experts have said the benefits to younger, healthy people aren't yet clear, and say new vaccines will likely need to be developed as the virus continues to mutate.
H.Romero--AT